Rudolph Abby E, Al Akoury Nadine, Bogdanenko Natalija, Markus Kristen, Whittle Isabelle, Wright Olivia, Haridy Hammam, Spinardi Julia R, McLaughlin John M, Kyaw Moe H
Pfizer Vaccines, Collegeville, USA.
Pfizer Emerging Markets, Aoukar, Lebanon.
Hum Vaccin Immunother. 2025 Dec;21(1):2474772. doi: 10.1080/21645515.2025.2474772. Epub 2025 Mar 13.
This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020-July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for the relationship between COVID-19 vaccination and Post-COVID-19 Condition (PCC) by timing of vaccination relative to infection or PCC-onset. Comparisons of adjusted vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) across study characteristics known to impact PCC burden or VE against other COVID-19 endpoints were possible for 31 studies where vaccination preceded infection. Seventy-seven percent of pre-infection aVE estimates were statistically significant (range: 7%-95%). Statistically significant pre-infection aVE estimates were slightly higher for mRNA (range: 14%-84%) than non-mRNA vaccines (range: 16%-38%) and aVE ranges before and during Omicron overlapped. Our findings suggest that COVID-19 vaccination before SARS-CoV-2 infection reduces the risk of PCC regardless of vaccine type, number of doses received, PCC definition, predominant variant, and severity of acute infections included.
本系统文献综述总结了56篇出版物和预印本(2020年1月至2023年7月)中的证据,这些文献基于JBI批判性评价,偏倚风险较低,报告了根据接种疫苗时间相对于感染或新冠后状况(PCC)发病时间对新冠疫苗接种与PCC之间关系的调整估计。对于31项接种疫苗先于感染的研究,可以比较已知会影响PCC负担的研究特征中针对≥1种PCC(与未接种疫苗者相比)的调整疫苗效力(aVE),或针对其他新冠终点的疫苗效力。感染前aVE估计值的77%具有统计学意义(范围:7%-95%)。mRNA疫苗(范围:14%-84%)的感染前aVE估计值在统计学上略高于非mRNA疫苗(范围:16%-38%),奥密克戎毒株出现之前和期间的aVE范围有重叠。我们的研究结果表明,在感染SARS-CoV-2之前接种新冠疫苗可降低PCC风险,无论疫苗类型、接种剂量、PCC定义、主要毒株以及所纳入急性感染的严重程度如何。